ClinicalTrials.gg
CompletedNCT02715726ODYSSEY EASTUpdated Sep 30, 2019Results posted

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

A Phase 3 interventional study of Alirocumab and Placebo for alirocumab in Hypercholesterolemia, sponsored by Sanofi. Completed at 62 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-30.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
615
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
8th of 43
615 · median 107
Started
2016
with 4 others
Phase 3
20 of 43
none open now
Registered
31st of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 8th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 31st registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy in comparison to ezetimibe 10 mg daily after 24 weeks of treatment in Asia in participants with hypercholesterolemia at high cardiovascular (CV) risk.

Secondary Objectives:

  • To evaluate the effect of alirocumab 75 mg in comparison with ezetimibe 10 mg on LDL-C after 12 weeks of treatment.
  • To evaluate the effect of alirocumab on other lipid parameters: e.g., apolipoprotein B (Apo B), non-high density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), lipoprotein a (Lp[a]), HDL-C, triglycerides (TG), apolipoprotein A-1 (Apo A-1).
  • To evaluate the safety and tolerability of alirocumab.
  • To evaluate the development of anti-alirocumab antibodies.
  • To evaluate the pharmacokinetics (PK) of alirocumab.
Read the detailed description

The maximum study duration was 35 weeks per participant, which included a screening period of up to 3 weeks, a 24-week randomized treatment period, and an 8-week post-treatment follow-up period.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who are not adequately controlled with a maximally tolerated daily dose of statin at a stable dose for at least 4 weeks prior to the screening visit (Week -3).

Exclusion criteria

Exclusion criteria:

  • Participants without established CHD or CHD risk equivalents.
  • LDL-C \<70 mg/dL (\<1.81 mmol/L) at the screening visit (Week -3) in participants with history of documented CV disease.
  • LDL-C \<100 mg/dL (\<2.59 mmol/L) at the screening visit (Week -3) in participants without history of documented CV disease.
  • Change in statin dose or dose regimen from screening to randomization.
  • Currently taking a statin other than atorvastatin, rosuvastatin, or simvastatin.
  • Atorvastatin, rosuvastatin, or simvastatin was not taken daily or not taken at a registered dose.
  • Daily doses above atorvastatin 80 mg, rosuvastatin 40 mg, or simvastatin 40 mg.
  • Use of cholesterol absorption inhibitor (ie, ezetimibe), omega-3 fatty acid (at doses ≥1000 mg daily), nicotinic acid, fibrates, bile acid-binding sequestrant, or red yeast rice products in the past 4 weeks prior to screening visit (Week -3).
  • Fasting serum triglycerides >400 mg/dL (>4.52 mmol/L) at the screening period.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
615 participants (actual)

Study arms

  • Active comparator
    Ezetimibe 10 mg

    Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).

    Drug: Placebo for alirocumab · Drug: ezetimibe · Drug: atorvastatin · Drug: rosuvastatin · Drug: simvastatin

  • Experimental
    Alirocumab 75 mg Q2W/up to 150 mg Q2W

    Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was \>=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter \[mmol/L\]) at Week 8.

    Drug: Alirocumab · Drug: placebo for ezetimibe · Drug: atorvastatin · Drug: rosuvastatin · Drug: simvastatin

Interventions

  • Pharmaceutical form:solution Route of administration: subcutaneous

    Also known as: SAR236553 (REGN727)

  • DrugPlacebo for alirocumab

    Pharmaceutical form:solution Route of administration: subcutaneous

  • Pharmaceutical form:capsule Route of administration: oral

  • Drugplacebo for ezetimibe

    Pharmaceutical form:capsule Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

  • Pharmaceutical form:tablet Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis

    Adjusted least square (LS) means and standard errors at Week 24 were obtained from mixed models analysis with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 24

  2. Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  3. Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 12

  4. Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  5. Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 24

  6. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  7. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 24

  8. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 up to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  9. Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  10. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  11. Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  12. Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis

    Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.

    Time frame: Up to Week 24

  13. Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis

    Adjusted percentages at Week 24 were obtained from multiple imputation approach including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

    Time frame: Up to Week 24

  14. Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis

    Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.

    Time frame: From Baseline to Week 24

  15. Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  16. Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis

    Adjusted means and standard errors at Week 24 were obtained by using multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  17. Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  18. Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis

    Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  19. Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  20. Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis

    Adjusted means and standard errors at Week 12 were obtained by using multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  21. Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

07

Results

Posted Sep 30, 2019

Participant flow

The study was conducted at 61 centers in China, India and Thailand. Overall 1163 participants were screened between 27 July 2016 and 18 December 2017, of whom 548 were screen failures. Screen failures were mainly due to exclusion criteria met. A total of 615 participants were randomized in 2:1 ratio to alirocumab: ezetimibe.

Participant flow — Overall Study
MilestoneEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Started208407
Treated207405
Safety population206406
Completed190380
Not completed1827
Withdrew: Adverse event26
Withdrew: Protocol violation10
Withdrew: Death21
Withdrew: Participant moved13
Withdrew: Other than specified above1115
Withdrew: Randomized but not treated12

Outcome measures

PrimaryPercent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis

Adjusted least square (LS) means and standard errors at Week 24 were obtained from mixed models analysis with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis-20.3 ± 2.0-56.0 ± 1.5
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -35.6 · 95% CI -40.6 to -30.7Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis-21.3 ± 2.0-58.7 ± 1.4
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -37.3 · 95% CI -42.1 to -32.6Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis-22.2 ± 1.9-57.1 ± 1.4
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -34.9 · 95% CI -39.5 to -30.2Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis-22.7 ± 1.9-58.1 ± 1.4
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -35.4 · 95% CI -40.0 to -30.7Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent Change
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis-16.2 ± 1.4-43.5 ± 1.0
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -27.4 · 95% CI -30.8 to -23.9Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent Change
Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis-17.4 ± 1.4-45.2 ± 1.0
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -27.8 · 95% CI -31.2 to -24.4Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent Change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis-19.4 ± 1.7-47.0 ± 1.2
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -27.7 · 95% CI -31.8 to -23.6Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent Change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis-20.4 ± 1.7-49.1 ± 1.2
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -28.7 · 95% CI -32.6 to -24.7Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 up to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent Change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis-13.8 ± 1.2-33.9 ± 0.9
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -20.2 · 95% CI -23.1 to -17.2Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent Change
Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis-16.5 ± 1.4-43.0 ± 1.0
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -26.5 · 95% CI -29.8 to -23.2Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent Change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis-20.7 ± 1.6-47.4 ± 1.1
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -26.7 · 95% CI -30.5 to -22.8Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent Change
Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis-14.9 ± 1.2-34.2 ± 0.8
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: -19.3 · 95% CI -22.1 to -16.5Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis

Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis
percentage of participantsEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis40.585.1
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 11.2 · 95% CI 7.1 to 17.7Alirocumab 75 mg Q2W/up to 150 mg Q2W vs Ezetimibe
SecondaryPercentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis

Adjusted percentages at Week 24 were obtained from multiple imputation approach including all available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis
percentage of participantsEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis42.187.0
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 13.6 · 95% CI 8.3 to 22.3Alirocumab 75 mg Q2W/up to 150 mg Q2W vs Ezetimibe
SecondaryPercent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis

Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent Change
Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis3.956 ± 2.095-30.317 ± 1.461
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Regression, Robust · p = <0.0001 (Threshold for significance at 0.05 level.) · Adjusted mean difference: -34.273 · 95% CI -39.262 to -29.285Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis6.5 ± 1.38.3 ± 0.9
Statistical analysis
  • Ezetimibe 10 mg vs Alirocumab 75 mg Q2W/up to 150 mg Q2W · Mixed Models Analysis · p = 0.2280 (Threshold for significance at 0.05 level.) · Ls mean difference: 1.9 · 95% CI -1.2 to 4.9Alirocumab 75 mg Q2W/up to 150 mg Q2W vs. Ezetimibe
SecondaryPercent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis

Adjusted means and standard errors at Week 24 were obtained by using multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis-14.409 ± 1.904-14.462 ± 1.341
SecondaryPercent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis-0.2 ± 0.83.2 ± 0.6
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis

Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent Change
Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis
percent ChangeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis6.313 ± 2.056-30.064 ± 1.449
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis6.1 ± 1.27.3 ± 0.9
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis

Adjusted means and standard errors at Week 12 were obtained by using multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis-13.585 ± 1.929-9.965 ± 1.379
SecondaryPercent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis
percent changeEzetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2W
Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis1.1 ± 0.83.7 ± 0.6

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to 32 weeks of the study regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe 10 mg3/206 (1.5%)23/206 (11.2%)41/206 (19.9%)
Alirocumab 75 mg Q2W/up150 mg Q2W2/406 (0.5%)41/406 (10.1%)71/406 (17.5%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventEzetimibe 10 mgAlirocumab 75 mg Q2W/up150 mg Q2W
Angina UnstableCardiac disorders0/2069/406
Acute Myocardial InfarctionCardiac disorders3/2063/406
PneumoniaInfections and infestations0/2064/406
Cardiac Failure CongestiveCardiac disorders2/2060/406
DeathGeneral disorders2/2060/406
Ischaemic StrokeNervous system disorders2/2060/406
Arteriosclerosis Coronary ArteryCardiac disorders1/2062/406
Cardiac FailureCardiac disorders1/2062/406
BronchitisInfections and infestations0/2062/406
Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders0/2062/406
Most frequent other events
Most frequent other events
EventEzetimibe 10 mgAlirocumab 75 mg Q2W/up150 mg Q2W
Upper Respiratory Tract InfectionInfections and infestations29/20654/406
Accidental OverdoseInjury, poisoning and procedural complications15/20627/406

Baseline characteristics

Analysis was performed on randomized participants.

Age, Continuous
Age, Continuous(Years)Ezetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2WTotal
Mean58.3 ± 11.258.8 ± 10.758.6 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2WTotal
Female6292154
Male146315461
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ezetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2WTotal
American Indian or Alaska Native000
Asian208407615
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Ezetimibe 10 mgAlirocumab 75 mg Q2W/up to 150 mg Q2WTotal
Mean2.875 ± 1.2872.862 ± 1.2532.866 ± 1.264
08

Study locations

62 sites
  • Investigational Site Number 1560027
    Beijing, 100029, China
  • Investigational Site Number 1560043
    Beijing, 100034, China
  • Investigational Site Number 1560039
    Beijing, 100053, China
  • Investigational Site Number 1560012
    Beijing, 100730, China
  • Investigational Site Number 1560018
    Beijing, 100730, China
  • Investigational Site Number 1560006
    Changchun, 130021, China
  • Investigational Site Number 1560020
    Changchun, 130021, China
  • Investigational Site Number 1560023
    Changsha, 410011, China
  • Investigational Site Number 1560030
    Fuzhou, 354200, China
  • Investigational Site Number 1560005
    Guangzhou, 510080, China
  • Investigational Site Number 1560040
    Guangzhou, 510080, China
  • Investigational Site Number 1560025
    Guangzhou, 510120, China
  • Investigational Site Number 1560048
    Hangzhou, 310014, China
  • Investigational Site Number 1560037
    Hangzhou, 310015, China
  • Investigational Site Number 1560008
    Hangzhou, 310016, China
  • Investigational Site Number 1560014
    Hohhot, 010017, China
  • Investigational Site Number 1560016
    Jinan, 250013, China
  • Investigational Site Number 1560044
    Lanzhou, 730000, China
  • Investigational Site Number 1560028
    Nanchang, 330006, China
  • Investigational Site Number 1560045
    Nanjing, 210006, China
  • Investigational Site Number 1560017
    Nanjing, 210008, China
  • Investigational Site Number 1560031
    Nanjing, 210011, China
  • Investigational Site Number 1560035
    Nanning, 530031, China
  • Investigational Site Number 1560029
    Shanghai, 200025, China
  • Investigational Site Number 1560041
    Shanghai, 200040, China
  • Investigational Site Number 1560053
    Shanghai, 201199, China
  • Investigational Site Number 1560009
    Shenyang, 110004, China
  • Investigational Site Number 1560001
    Shenyang, 110016, China
  • Investigational Site Number 1560042
    Shenyang, 110016, China
  • Investigational Site Number 1560036
    Shenzhen, 518036, China
  • Investigational Site Number 1560056
    Siping, 136000, China
  • Investigational Site Number 1560021
    Taiyuan, 030001, China
  • Investigational Site Number 1560002
    Tianjin, 300052, China
  • Investigational Site Number 1560022
    Tianjin, 300121, China
  • Investigational Site Number 1560052
    Tianjin, 300140, China
  • Investigational Site Number 1560055
    Wenzhou, 325000, China
  • Investigational Site Number 1560003
    Wuhan, 430022, China
  • Investigational Site Number 1560004
    Xi'An, 710061, China
  • Investigational Site Number 1560019
    Xuzhou, 221002, China
  • Investigational Site Number 1560054
    Yinchuan, 750004, China
  • Investigational Site Number 1560057
    Zhanjiang, 524001, China
  • Investigational Site Number 3560017
    Belgaum, 590010, India
  • Investigational Site Number 3560001
    Gurgaon, 122001, India
  • Investigational Site Number 3560003
    Hubli, 580021, India
  • Investigational Site Number 3560010
    Kolkata, 700020, India
  • Investigational Site Number 3560019
    Kolkata, 700073, India
  • Investigational Site Number 3560020
    Mangalore, 575002, India
  • Investigational Site Number 3560006
    Mumbai, India
  • Investigational Site Number 3560007
    Nagpur, 440003, India
  • Investigational Site Number 3560004
    Nagpur, 440010, India
  • Investigational Site Number 3560008
    Nagpur, 440012, India
  • Investigational Site Number 3560016
    Nagpur, 440012, India
  • Investigational Site Number 3560014
    New Delhi, 110002, India
  • Investigational Site Number 3560005
    Pune, 411001, India
  • Investigational Site Number 3560011
    Pune, 411001, India
  • Investigational Site Number 3560013
    Surat, 395002, India
  • Investigational Site Number 3560015
    Vijayawada, 520008, India
  • Investigational Site Number 3560012
    Vijaywada, 520002, India
  • Investigational Site Number 7640003
    Bangkok-Noi, 10700, Thailand
  • Investigational Site Number 7640004
    Bangkok, 10400, Thailand
  • Investigational Site Number 7640001
    Muang, 50200, Thailand
  • Investigational Site Number 7640002
    Pratumwan, 10400, Thailand
09

References and documents

Publications

  • Han Y, Chen J, Chopra VK, Zhang S, Su G, Ma C, Huang Z, Ma Y, Yao Z, Yuan Z, Zhao Q, Kuanprasert S, Baccara-Dinet MT, Manvelian G, Li J, Chen R. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J Clin Lipidol. 2020 Jan-Feb;14(1):98-108.e8. doi: 10.1016/j.jacl.2019.10.015. Epub 2019 Nov 18. PubMed 31882376 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Aug 2018, 24 months.

Results were first posted in Sep 2019, 1 year 1 month after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 24 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2016
First posted
Mar 22, 2016
StartActual
Jul 27, 2016
Primary completionActual
Aug 6, 2018
CompletionActual
Aug 6, 2018
Results first posted
Sep 30, 2019
Last update
Sep 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02715726
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 22, 2016
Start date
Jul 27, 2016
Primary completion
Aug 6, 2018
Completion
Aug 6, 2018
Results posted
Sep 30, 2019
Last update
Sep 30, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion